Korean Journal of Nephrology 2008;27(6):707-711.
The Effect of Intraperitoneal Calcitriol Pulse Therapy in CAPD Patients with Secondary Hyperparathyroidism.
Ho Cheol Song, M.D., Yoo Sun Hong, M.D., Hyun Wha Jeong, M.D., Yong Gyun Kim, M.D., Seok Joon Shin, M.D., Byung Soo Kim, M.D., Young Ok Kim, M.D., Yong Soo Kim, M.D. and Euy Jin Choi, M.D.
Department of Internal Medicine, College of Medicine The Catholic University of Korea, Seoul, Korea
임상연구 : 복막투석환자에서 복강 내 칼시트리올 충격요법의 부갑상선 호르몬 억제효과
송호철, 유선홍, 정현화, 김용균, 신석준, 김병수, 김영옥, 김용수, 최의진
가톨릭대학교 의과대학 내과학교실
Abstract
Purpose : In hemodialysis patients with secondary hyperparathyroidism, intravenous administration of calcitriol became widely utilized. In CAPD patients, however, the intravenous administration of calcitriol is not practical. The purpose of the present study was to determine the effect and safety of intraperitoneal (IP) calcitriol pulse therapy in CAPD patients. Methods : All patients undergoing CAPD between January 2006 and January 2007 and willing to give informed consent were eligible. Inclusion criteria were age greater 18 years, on CAPD for at least 6 months, and secondary hyperparathyroidism (intact PTH >300 pg/mL). Intraperitoneal calcitriol was given by direct infusion into the dialysate (2.0 μg) twice per week. If hypercalcemia (>10.5 mg/dL) and hyperphosphatemia (>6.5 mg/dL) developed, the patients were excluded from study. Results : Eighteen patients were enrolled into the study. Among them, 16 patients completed the study period. After IP calcitriol for 3 months, there was a significant drop of iPTH level from the pretreatment level of 490±234 pg/mL to the level of 318±315 pg/mL (p<0.05). There were no definite hypercalcemia during the study period, and only 1 patient was excluded from study due to hyperphosphatemia. Conclusion : In CAPD patients, IP calcitriol pulse therapy is effective in treating secondary hyperparathyroidism, and that IP calcitriol pulse therapy is associated with a low incidence of hypercalcemia and hyperphosphatemia.
Key Words: Calcitriol, Injections, Intraperitoneal, Peritoneal Dialysis


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736    Fax: +82-2-3486-8737    E-mail: registry@ksn.or.kr                

Copyright © 2024 by The Korean Society of Nephrology.

Developed in M2PI

Close layer